Vaibhav Sahai

This study identifies treatment-associated biomarkers in pancreatic ductal adenocarcinoma using serum extracellular vesicle proteomics, finding platelet-related changes linked to survival and therapy response.

The paper analyzes matched pre- and post-chemotherapy biospecimens in pancreatic cancer, revealing that cancer-associated fibroblasts undergo neural reprogramming, characterized by axonal guidance gene enrichment, which may contribute to chemoresistance and tumor progression.

This study identifies a stress-lipid kinase axis in NEPC driven by PIKfyve, revealing a synthetic vulnerability between PIKfyve and FASN that can be exploited for therapeutic targeting.

This study isolates and characterizes microbiota from human pancreatic tumors and small intestine, revealing how a Klebsiella oxytoca strain affects the tumor microenvironment and therapy response.

The paper identifies a KRT17-positive, low-grade epithelial population in IPMNs with malignant features using spatial transcriptomics and single-cell RNA sequencing.

This study identifies PIKfyve as a targetable vulnerability in pancreatic cancer by showing its role in lipid metabolism and synthetic lethality with KRAS-MAPK inhibitors.

This study evaluates the diagnostic sensitivity of the MED-Amp assay for detecting rare KRAS mutations in ctDNA from localized pancreatic cancer patients, showing improved detection at low DNA input and correlation with survival outcomes.